# CLINICAL CASE DETAILS & REQUEST FOR EXPERT MEDICAL OPINION **Patient Profile:** - **Age:** 23 Years Old - **Gender:** Female - **Marital Status:** Unmarried - **Current Location:** India (May 2026) --- ## 1. PRESENT COMPLAINT & CHRONOLOGY - **Day 1-2 (Onset):** Started with acute throat discomfort, soreness, and progressive upper respiratory symptoms (cold/nasal congestion). - **Day 3-4 (Progression):** Throat discomfort worsened significantly. Developed high-grade fever and severe, frequent coughing. - **Current Status (Last 48 Hours):** Sustained high-grade fever that spikes repeatedly. Severe generalized body aches (myalgia), extreme fatigue, and profound low energy due to the fever. ## 2. SYMPTOMS IN DETAIL - **Fever Pattern:** High-grade, persistent fever for the last 2 days. It responds temporarily to Paracetamol (PCM) but spikes aggressively once the antipyretic effect wears off. - **Cough Profile:** Frequent, exhausting cough. Phenotypically presents as a dry, hacking cough, but the patient reports a distinct subjective sensation of heavy mucus/phlegm trapped deep within the chest/airways that is thick and cannot be expectorated. - **Nasal/Throat Symptoms:** Active cold symptoms, nasal congestion, and a sensation of post-nasal drip triggering the cough and throat irritation. - **Systemic Symptoms:** Severe body pain, joint stiffness, and acute lethargy. ## 3. RECENT MEDICATION HISTORY - **Paracetamol (PCM):** Taken for fever; provides transient relief only. - **Allegra 120 mg (Fexofenadine):** Taken for potential allergic/antihistamine coverage, but has not provided significant relief from the cough, fever, or chest congestion. --- ## 4. CLINICAL REQUEST (WORLD-CLASS EXPERT APPROACH) Using evidence-based internal medicine and respiratory guidelines, please provide a comprehensive clinical analysis addressing the following: ### A. Differential Diagnosis (What could this be?) - Differentiate between a severe viral prodrome, Acute Bacterial Sinusitis with Post-Nasal Drip, Acute Bronchitis, or an atypical bacterial lower respiratory tract infection (given the recurrent nature of her symptoms and high-grade fever). ### B. Gold-Standard Diagnostic Tests - Recommend the exact laboratory investigations (e.g., CBC with differential, CRP, Throat Swab/Sputum Culture) and imaging (e.g., Chest X-ray PA view) required to pinpoint the etiology safely and rule out lower respiratory complications. ### C. Safe and Effective Empirical Treatment Plan Outline a comprehensive pharmacological and supportive management strategy, specifying the role, mechanisms, and safety profiles of: 1. **Targeted Antibiotic Therapy:** (e.g., Macrolides like Azithromycin vs. Beta-lactams), including exact criteria for starting them. 2. **Mucolytics/Expectorants:** To specifically address the "trapped mucus" sensation despite a dry-sounding cough (e.g., Ambroxol/Ambrolite mechanism). 3. **Optimized Antipyretic & Pain Management:** How to safely manage the high-grade fever and severe body aches without causing hepatotoxicity or gastric irritation. 4. **Supportive Care:** Non-pharmacological lifestyle corrections, hydration targets, and steam protocols. ### D. Red Flags & Warning Signs - List the specific clinical signs (e.g., dyspnea, oxygen saturation drop, wheezing) that would necessitate immediate emergency medical attention.

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"acute bronchitis" OR "upper respiratory infection" management treatment

Searching the Web

influenza vs acute bronchitis high fever persistent cough India 2026 empirical treatment guidelines

Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
I now have comprehensive data from Harrison's, Tintinalli's, the ICMR guidelines, and current India H3N2 outbreak context. Let me compile the full expert clinical opinion.

Expert Clinical Opinion — 23F, Acute Febrile Respiratory Illness (India, May 2026)

Disclaimer: This is a detailed educational clinical analysis based on authoritative medical textbooks and current evidence. It is not a substitute for in-person evaluation by a licensed physician. Please consult a doctor before initiating any prescription medication.

A. DIFFERENTIAL DIAGNOSIS

The Clinical Pattern

This patient's symptom arc — 2 days of URI symptoms → progression to high-grade fever + severe cough + myalgia + profound fatigue by days 3–4 — is a classic influenza-like illness (ILI) presentation. The key differentiating features are mapped below.
FeatureInfluenza (ILI)Acute Viral BronchitisAcute Bacterial SinusitisAtypical Pneumonia (Mycoplasma)
OnsetAbrupt/rapidGradualDays 7–10 of URIGradual over 1–2 weeks
FeverHigh-grade, spikingLow to moderateLow to moderateVariable
Myalgia/FatigueSevere, hallmarkMildAbsent/mildModerate
CoughDry, exhaustingProminent, persistentPostnasal drip-drivenDry, "walking pneumonia"
Congestion/rhinorrheaPresentPresentThick purulent dischargeMinimal
Course by Day 4Peak severityStill earlyStill buildingStill early
Most Likely Diagnosis: Influenza-like illness (ILI) — specifically consistent with Influenza A (H3N2), which has been circulating extensively in India as of 2026. H3N2 characteristically causes more severe and prolonged illness than seasonal influenza, with sudden high fever, sore throat, myalgia, dry hacking cough, and severe fatigue. The "trapped mucus" sensation despite a dry-sounding cough is explained by bronchial mucosal inflammation and viscous secretions that cannot be mobilized effectively.
Secondary Consideration: Acute Bronchitis — complicating the ILI, given the chest congestion component. Acute bronchitis is defined as cough lasting >5 days with airway inflammation; the bronchial hyperresponsiveness from viral infection explains the subjective thick mucus sensation even in the absence of frank expectoration (Tintinalli's Emergency Medicine).
Third Consideration: COVID-19 — must always be considered in India 2026. Fever + cough + myalgia + fatigue overlaps significantly. However, the prominent sore throat at onset and absence of anosmia/ageusia makes COVID-19 slightly less likely — though co-infection is possible.
Less Likely Right Now:
  • Acute Bacterial Sinusitis (ABS): Requires symptoms ≥10 days without improvement, OR a "double-worsening" pattern (improved then re-worsened), OR fever ≥39°C with facial pain/purulent discharge. This patient is day 4–5 — too early to diagnose ABS, though post-nasal drip from viral sinusitis is clearly contributing.
  • Mycoplasma pneumonia: Typically presents as sub-acute, less explosive onset without the degree of myalgia. However, if fever and cough persist beyond 7–10 days with minimal improvement, this escalates in priority.
  • Streptococcal Pharyngitis: Can cause high fever and sore throat, but lacks cough and myalgia as dominant features.
Harrison's Principles of Internal Medicine (22E, 2025) explicitly notes: "SARS-CoV-2... can cause virtually any upper respiratory symptom... Any respiratory symptom occurring in areas where SARS-CoV-2 is circulating should be considered a potential manifestation of COVID-19."

B. GOLD-STANDARD DIAGNOSTIC INVESTIGATIONS

Tier 1 — Immediate (Do These Now)

TestRationaleExpected Finding in ILI
CBC with differentialDifferentiate viral vs bacterial; assess severityLeukopenia or normal WBC; lymphopenia typical of influenza; high WBC with neutrophilia → bacterial
CRP (C-Reactive Protein)Inflammatory marker; helps triage antibiotic needMildly elevated in viral; markedly elevated (>50–100 mg/L) suggests bacterial co-infection
Rapid Antigen Test — Influenza A/BPoint-of-care; result in 15–30 minutesPositive confirms influenza; negative does NOT rule it out (50–70% sensitivity)
Rapid Antigen Test / RT-PCR — SARS-CoV-2Mandatory to exclude COVID-19 in 2026 IndiaPositive changes management
SpO₂ (Pulse Oximetry)Non-invasive; critical triage tool<94% = danger signal requiring escalation

Tier 2 — If Fever Persists >5 Days or Clinical Deterioration

TestRationale
Chest X-ray PA viewRule out pneumonia; look for consolidation, infiltrates, pleural effusion
Sputum Gram stain + cultureOnly meaningful if productive sputum develops
Throat swab for Strep rapid test / cultureIf pharyngeal exudates appear
ESRNon-specific but helps trend severity
Liver function tests (LFT)If Paracetamol has been used repeatedly at high doses
Multiplex respiratory PCR panelIf available; detects influenza A/B, RSV, Mycoplasma, COVID-19 simultaneously
Note on Procalcitonin: Harrison's and Tintinalli's both now discourage routine procalcitonin use to guide antibiotic decisions in outpatient acute respiratory infections — large RCTs showed it did not reduce unnecessary antibiotic prescribing in this setting.

C. COMPREHENSIVE TREATMENT PLAN

C1. Should Antibiotics Be Started?

At Day 4–5 of illness, with no confirmed bacterial source, antibiotics are NOT indicated empirically. This is among the most evidence-supported positions in modern infectious disease.
Harrison's (22E): "The only common acute respiratory infections that should be treated with antibiotics are AOM, sinusitis, streptococcal pharyngitis, and pneumonia. Common respiratory viruses cause the overwhelming majority of acute respiratory infections, and these infections are generally self-limited; antibiotics neither speed resolution nor prevent complications."
Tintinalli's Emergency Medicine: "Antibiotics do not provide significant benefit in patients with acute bronchitis."
Antibiotic criteria — start ONLY if:
ConditionAntibiotic of ChoiceRationale
Fever persists beyond Day 7–10 with worsening sinus pain, purulent nasal dischargeAmoxicillin-Clavulanate 625mg TDS × 5–7 daysCovers H. influenzae (30% beta-lactamase producers in India), S. pneumoniae, Moraxella
Suspected Mycoplasma/Chlamydia pneumoniae (atypical): dry cough >10 days, bilateral infiltratesAzithromycin 500mg Day 1 → 250mg Days 2–5Macrolides are drug of choice for atypicals; note growing macrolide resistance in India
Confirmed or strongly suspected Strep pharyngitis (exudates + tender nodes + no cough)Amoxicillin 500mg TDS × 10 days (or Penicillin V)Beta-lactam is still first line; azithromycin only if penicillin-allergic
Chest X-ray shows community-acquired pneumoniaAmoxicillin-Clavulanate OR Azithromycin, depending on severity and sputum pattern
Regarding Azithromycin vs Beta-Lactams in India: Murray & Nadel's Respiratory Medicine notes that macrolide resistance is rising. For H. influenzae, amoxicillin-clavulanate is preferred over azithromycin, while azithromycin remains best for atypicals. Self-prescribing azithromycin for a viral ILI is strongly discouraged — it contributes to resistance and provides no benefit.

C2. Mucolytics — Addressing the "Trapped Mucus" Sensation

The subjective sensation of thick mucus that cannot be expelled despite a predominantly dry cough is caused by:
  1. Bronchial mucosal edema and hypersecretion from viral infection
  2. Post-nasal drip pooling in the hypopharynx and triggering cough
  3. Dehydration (fever increases insensible losses, thickening secretions)
Recommended agents:
DrugDoseMechanismEvidence
Ambroxol (Ambrolite/Mucosolvan)30mg TDS (oral)Stimulates surfactant production → reduces mucus viscosity; also has mild local anesthetic effect on airway mucosa reducing cough sensitivity; stimulates ciliary beat frequencyWell-supported for symptom relief in acute bronchitis
Guaifenesin (Mucinex/Grilinctus)400mg every 4hExpectorant; increases respiratory tract fluid secretion, reducing mucus viscosity and aiding expectorationModest cough relief; endorsed by Tintinalli's
Steam inhalation2–3× daily, 10 minHumidifies airways, loosens viscous secretions, reduces nasal congestion; can add menthol/eucalyptusFree, safe, highly effective
Saline nasal spray / rinse2–3× dailyIrrigates post-nasal secretions, reduces congestion driving the coughFirst-line non-pharmacological measure
Note on Fexofenadine (Allegra 120mg): Fexofenadine is a second-generation, non-sedating antihistamine. It works well for allergic rhinitis but has minimal efficacy in viral URI/ILI because the congestion and symptoms are driven by viral-induced cytokine release, not histamine. This explains why it hasn't helped. A first-generation antihistamine with decongestant (e.g., Chlorpheniramine + Phenylephrine / Cetcold-type combinations) would be more useful for the nasal/post-nasal component, though the CNS sedation and cardiac effects must be considered.

C3. Fever & Pain Management — Safe Protocol

Goal: Prevent fever spikes, manage myalgia, avoid hepatotoxicity.
DrugDose & ScheduleSafety Points
Paracetamol (PCM/Acetaminophen)500–1000mg every 6 hours (max 4g/24h)Safe. The most common error is dosing only when fever spikes (reactive) — scheduled dosing every 6h prevents the spike-rebound cycle. Avoid if liver disease, alcohol use
Ibuprofen 400mgEvery 6–8h WITH foodMore effective anti-inflammatory; better for myalgia/joint ache than PCM alone. Take with food or antacid to prevent gastric irritation. Avoid if peptic ulcer disease, renal impairment, dehydration
Alternating PCM + IbuprofenStagger: PCM at 0h and 6h, Ibuprofen at 3h and 9hEvidence-supported strategy for high-grade fever. Gives antipyretic coverage every 3h without exceeding maximum dose of either. Significantly better fever control than either alone
NimesulideAvoidHepatotoxic risk; banned/restricted for children, caution in adults; not recommended in febrile illness
Hepatotoxicity Warning: PCM is safe at recommended doses. The danger zone is >4g/day, especially combined with:
  • Other paracetamol-containing combination products (cold syrups, Combiflam — check labels)
  • Alcohol
  • Pre-existing liver disease

C4. Supportive Care (Equally Important as Medications)

MeasureTarget/ProtocolRationale
Oral hydration2.5–3L fluids/day (water, ORS, coconut water, warm soups, herbal teas)Fever increases insensible water loss. Dehydration thickens secretions, worsens headache, and can cause fever to be self-perpetuating
Rest — strict bed restMinimum 5–7 days of activity restrictionILI with severe myalgia requires rest; exertion can trigger post-viral fatigue syndrome and rare myocarditis
Steam inhalation2–3× daily, 10 min, 45–50°C waterMucus mobilization, nasal decongestion, soothes airways
Saline garglesWarm saline (1/2 tsp salt in 1 cup warm water), 3–4× dailyMechanically clears pharyngeal secretions, reduces sore throat
Sleep positioningHead-of-bed elevation (30–45°)Reduces post-nasal drip triggering nocturnal cough
NutritionLight, easily digestible meals; avoid dairy if it seems to increase mucus sensationImmune function requires adequate protein/caloric intake
Oseltamivir (Tamiflu)75mg BD × 5 days — only if started within 48h of symptom onsetPer ICMR guidelines and CDC Yellow Book 2026: reduces symptom duration by ~1 day and reduces viral shedding. At day 4–5, the window has likely passed — but a physician should assess this
Avoid NSAIDs on empty stomachAlways with foodPrevents gastric erosion
Avoid codeine/opioid cough suppressantsNot indicatedCan suppress productive cough and impair mucus clearance

D. RED FLAGS — SEEK EMERGENCY CARE IMMEDIATELY

Do not wait or manage at home if any of the following appear:

Respiratory Red Flags

  • SpO₂ < 94% on pulse oximeter (normal is ≥95%)
  • Breathing rate > 30 breaths/minute at rest
  • Audible wheeze or stridor — new onset
  • Sensation of air hunger or difficulty completing sentences
  • Chest pain on deep inspiration (pleuritis / pneumonia)
  • Coughing up blood (hemoptysis)

Systemic Red Flags

  • Fever persisting beyond Day 7 with no improvement despite symptomatic treatment
  • Fever > 40°C (104°F) that does not respond to antipyretics within 1–2 hours
  • Confusion, disorientation, or altered mental status
  • Inability to maintain oral hydration — persistent vomiting, severe lethargy
  • Lips or fingernails turning blue/grey (cyanosis — emergency)
  • Severe chest tightness or heaviness (distinct from cough-related discomfort)
  • Rash appearing on skin (suggestive of secondary bacterial infection, dengue, or drug reaction)
  • Sudden worsening after initial improvement ("double-worsening" — suggests secondary bacterial sinusitis or pneumonia)
The IMA India stepwise acute fever guidelines specifically state: "Patients should be warned about symptoms which indicate complications like breathing difficulty, persistent fever beyond 4–5 days, or ear pain."

Summary Action Plan (Immediate Steps)

  1. Today: Visit a clinic or hospital for a CBC, CRP, SpO₂, and Rapid COVID-19 test. Request an influenza rapid antigen test if available. This rules out bacterial infection, pneumonia, and COVID-19 in one visit.
  2. Antipyretics: Switch from reactive PCM dosing to scheduled PCM 500–1000mg every 6 hours. Add Ibuprofen 400mg (with food) staggered every 3h between PCM doses for better fever + myalgia control.
  3. Mucolytic: Start Ambroxol 30mg TDS + steam inhalation 2–3× daily + warm saline gargling.
  4. Hydration: Target 2.5–3L fluids/day regardless of appetite.
  5. Stop Fexofenadine — it is not helping and is unlikely to be indicated here.
  6. Do not self-start antibiotics until a clinician reviews the blood results and clinical picture.
  7. Monitor SpO₂ — a basic pulse oximeter (~₹500–800) is a valuable home monitoring tool during this illness.
  8. If any red flag above appears, go to an Emergency Department immediately.

Sources: Harrison's Principles of Internal Medicine 22E (2025) | Tintinalli's Emergency Medicine | Murray & Nadel's Textbook of Respiratory Medicine | Red Book 2021 (AAP) | ICMR Antimicrobial Treatment Guidelines (2019) | IMA India Acute Fever Management Algorithm | CDC Yellow Book 2026 (Influenza chapter)

History of Present Illness (Past Episodes): The patient experienced an identical episode previously, which persisted for an entire month causing significant distress. Since that initial episode, the patient's respiratory system has become highly sensitive; consuming any cold food or beverages immediately triggers throat discomfort and reinstates the entire symptom cycle

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"post-infectious cough" OR "cough variant asthma" airway hyperresponsiveness

Searching the Web

post-infectious bronchial hyperreactivity cold food triggers throat cough recurrent respiratory illness management

Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"cough variant asthma" diagnosis treatment bronchial hyperresponsiveness

Reading File
Finding Sources
I now have everything needed. This new history fundamentally changes — and sharpens — the clinical picture.

Addendum: Revised Clinical Analysis — Recurrent Episodes + Post-Illness Respiratory Hypersensitivity

This additional history is clinically transformative. It is no longer appropriate to view the current episode in isolation. Two key new facts demand a complete diagnostic reframing:
  1. A prior identical episode lasting a full month — this rules out simple, uncomplicated viral ILI as the complete story
  2. Persistent airway hypersensitivity between episodes — specifically, cold food/beverages reliably triggering throat discomfort and reinstating the full symptom cycle
This symptom pattern has a precise clinical name and mechanism.

The New Central Diagnosis: Post-Infectious Bronchial Hyperresponsiveness (BHR) / Cough Hypersensitivity Syndrome

What Is This, Exactly?

When a viral respiratory infection causes significant mucosal injury to the airways (pharynx, larynx, trachea, bronchi), it can leave behind persistent sensitization of sensory nerve endings — specifically, the C-fiber cough receptors and rapidly-adapting stretch receptors (RARs) that line the airway mucosa. After the acute infection clears, these nerve endings remain in a lowered-threshold, hair-trigger state for weeks to months.
This is called:
  • Post-infectious cough hypersensitivity (the dominant mechanism here)
  • Viral-induced bronchial hyperresponsiveness (BHR) — confirmed by research showing viral infections stimulate bronchospastic inflammatory mediators, cause epithelial desquamation, and induce an autonomic imbalance in airway smooth muscle control
The result is that stimuli that are normally completely harmless — cold food, cold beverages, cold air, strong smells, talking, laughing, dry air — breach the lowered threshold and trigger:
  • Immediate throat discomfort
  • Cough
  • Airway narrowing sensation
  • And, critically, reinstatement of the full inflammatory cascade if the patient is re-exposed to a virus during this sensitized state
Harrison's (22E): "A distinct 'cough hypersensitivity syndrome' has emerged, emphasizing the putative role of sensitized sensory nerve endings and afferent neural pathways in causing chronic refractory cough, akin to chronic neuropathic pain. It presents with a dry or minimally productive cough and a tickle or sensitivity in the throat... It is more common in women than men and can last for years."
This is exactly what this patient is describing: a tickle/sensitivity persisting between infections, triggered by cold, more common in young women.

Why Did the First Episode Last a Full Month?

A standard viral ILI resolves in 7–14 days. A one-month course with significant distress suggests one or more of the following occurred:
Contributing FactorExplanation
Post-viral BHR extending the inflammatory phaseAirway inflammation persists weeks after viral clearance; each re-exposure to cold/irritants re-triggers it, creating a self-perpetuating cycle
Untreated Upper Airway Cough Syndrome (UACS)Persistent post-nasal drip from inflamed nasal/sinus mucosa chronically stimulating pharyngeal cough receptors
Possible undiagnosed Cough-Variant Asthma (CVA)CVA is asthma in which cough is the sole or dominant symptom — no classic wheeze or breathlessness required. Triggered by cold, viral infections, exercise. Spirometry may be normal between episodes
Secondary bacterial sinusitisIf the original episode was not properly managed, bacterial superinfection of the sinuses could have sustained fever and inflammation for 4+ weeks

Revised Differential Diagnosis — Current Episode in This New Context

DiagnosisProbabilityKey Supporting Feature
ILI/Influenza A (H3N2) on background of BHRVery highAcute onset + fever + myalgia + prior identical episode; now with sensitized airways making severity worse
Cough-Variant Asthma (CVA) presenting as recurrent ILIModerate-highCold trigger, recurrent cycle, female sex, no wheeze (CVA has no wheeze)
Cough Hypersensitivity Syndrome (CHS)ModerateThroat sensitivity between episodes, cold food trigger, female, dry tickle cough pattern
Allergic Rhinitis + Upper Airway Cough SyndromeModeratePost-nasal drip driving cough; fexofenadine partially indicated but not sufficient alone for viral superimposition
Simple recurrent viral ILILow (no longer sufficient explanation)Doesn't explain inter-episode hypersensitivity

Revised & Expanded Diagnostic Workup

Acute Phase (Do During This Illness)

Same as previously recommended: CBC, CRP, SpO₂, COVID-19 test, Influenza rapid antigen.

Additional Investigations for the Underlying Condition (Do After Recovery, Within 2–4 Weeks)

These are now essential — they address the root cause, not just the acute episode:
TestPurposeClinical Significance
Spirometry with bronchodilator reversibilityScreens for obstructive airway disease; looks for reversible airflow limitationNormal FEV1/FVC between episodes does NOT rule out CVA or BHR
Methacholine / Mannitol bronchoprovocation challenge testGold standard for BHRConfirms airway hyperresponsiveness even when resting spirometry is normal
Fractional exhaled Nitric Oxide (FeNO)Eosinophilic airway inflammation markerElevated in CVA and eosinophilic bronchitis; guides steroid therapy
Skin prick test / Specific IgE (RAST) panelAllergy workup — dust mites, mold, pollen, pet danderIf positive → atopic background driving BHR; requires allergen avoidance
Nasal endoscopy / ENT reviewAssess for chronic sinusitis, nasal polyps, deviated septumStructural source of ongoing post-nasal drip
Sputum eosinophil countIf CVA or eosinophilic bronchitis suspectedEosinophilia in sputum = corticosteroid-responsive condition
Anti-nuclear antibody (ANA), anti-dsDNA (if systemic symptoms)Rule out autoimmune cause of recurrent inflammatory episodesLow priority unless joints/skin also involved

Revised Management Plan — Treating Both the Acute Episode AND the Root Cause

Phase 1: Acute Management (Current Episode — Same as Before, with Additions)

All prior recommendations remain valid. Add the following:
DrugDoseRationale in This Context
Montelukast (Singulair) 10mg once nightly10mg OD at bedtimeLeukotriene receptor antagonist; reduces airway inflammation and hyperresponsiveness; particularly effective for viral-triggered bronchoconstriction and cold-air–induced cough. Widely available in India. Extremely safe
Levosalbutamol/Salbutamol inhaler (Asthalin/Levolin)2 puffs (100mcg each) via MDI + spacer, PRN or QIDShort-acting bronchodilator; rapidly relieves bronchospasm and the sensation of trapped air/chest tightness; addresses the BHR component. The "chest tightness with mucus" sensation likely has a significant bronchoconstriction component, not just mucus
Budesonide inhaled (100–200 mcg BD)Via puffer or nebulizerConsider if symptoms worsen or cough becomes dominant; inhaled corticosteroid is the evidence-based treatment for both CVA and post-viral BHR; suppresses the sensitized airway inflammation at its source

Phase 2: Inter-Episode Management (Between Attacks — THE Critical Phase)

This is where the cycle gets broken. This phase is currently being neglected, which is why episodes keep recurring with increasing severity.
StrategyDetailsGoal
Inhaled Corticosteroid (ICS) maintenanceBudesonide 100–200mcg BD × minimum 8–12 weeks after recoveryCalms the chronically sensitized airway; reduces threshold for re-triggering; prevents the next episode from being as severe or prolonged
Montelukast continuation10mg nightly for 3 monthsAnti-leukotriene protection against cold-air and viral triggers
Strict cold avoidance protocolNo cold water/ice beverages, no cold food directly from refrigerator, no cold air exposure without scarf/mask over mouthDirect trigger avoidance during the sensitized inter-episode window
Warm-temperature foods and beveragesAll liquids consumed at room temperature or warmPrevents thermal stimulation of sensitized pharyngeal/laryngeal cough receptors
Nasal saline irrigation dailyNeti pot or saline spray, morning and nightClears residual post-nasal secretions that chronically irritate sensitized throat receptors
Annual influenza vaccinationInactivated quadrivalent influenza vaccineThe single most effective intervention to prevent the triggering infection; in patients with BHR, influenza causes disproportionately severe and prolonged illness
Avoid NSAIDs (Ibuprofen) long-termEspecially if aspirin/NSAID sensitivity is ever suspected~10–20% of patients with BHR/CVA have aspirin-exacerbated respiratory disease (AERD); if ibuprofen ever seems to worsen cough/wheeze, stop immediately
ENT + Pulmonologist referralAfter recoveryFormal evaluation of sinuses and airway function; pulmonologist can perform bronchoprovocation testing and titrate ICS therapy properly

What Explains the "Cold Food = Full Symptom Restart" Phenomenon — Mechanistically

When cold food or liquid contacts the hypopharynx (back of the throat) and larynx:
  1. Thermal stimulation activates the already-sensitized TRPA1 and TRPV1 receptors in the airway mucosa (the same receptors that menthol activates, but in reverse — cold rather than cooling)
  2. This triggers an axon reflex in the sensitized C-fibers → releases substance P and CGRP locally → neurogenic inflammation of the mucosal lining
  3. The neurogenic inflammation → mucosal edema, increased secretions, mucus gland stimulation → reinstates the "congested" sensation
  4. Simultaneously, reflex bronchoconstriction of smooth muscle → chest tightness and reduced mucociliary clearance
  5. The body interprets this as a new infection signal → activates the immune cascade, which may lower the immune threshold for the next viral infection to take hold
This is not psychological. It is a well-characterized neuropathic airway phenomenon — structurally similar to how a healed burn scar remains hypersensitive to touch for months.

Long-Term Outlook and Prognosis

ScenarioPrognosis
With proper management (ICS + Montelukast + trigger avoidance + vaccination)Excellent — episodes should become shorter, milder, and less frequent; BHR typically resolves over 3–12 months
Without treatment (current approach)Each severe viral episode re-injures already-sensitized airways → progressive lowering of the trigger threshold → risk of progression to persistent asthma in a small percentage of cases
If CVA is confirmedRequires long-term ICS; fully treatable and compatible with normal life
The one-month prior episode and the current severe recurrence are warning signals that this airway is progressively more vulnerable with each cycle. Breaking the cycle now — with a proper pulmonologist workup after recovery — is the most important clinical priority beyond managing the acute illness.

Priority Action Summary

PriorityActionTimeframe
1Manage acute fever/cough as previously outlined + add Salbutamol inhaler (PRN) + Montelukast 10mg nightlyToday/Tomorrow
2Visit clinic for CBC, CRP, SpO₂, COVID/Flu testWithin 24–48 hours
3Strict avoidance of ALL cold foods and beverages until full recoveryImmediate and ongoing
4After recovery (2–4 weeks): Spirometry + FeNO + allergy testing + ENT reviewPost-recovery
5Annual influenza vaccine before next monsoon/winter seasonThis year
6Formal pulmonologist consultation to assess for CVA and titrate ICSWithin 1 month of recovery

Sources: Harrison's Principles of Internal Medicine 22E (2025) | Tintinalli's Emergency Medicine | Cox JK et al., "Cough-Variant Asthma: A Review of Clinical Characteristics, Diagnosis, and Pathophysiology," J Allergy Clin Immunol Pract 2025 [PMID 39557293] | Bronchial hyperreactivity viral-induced mechanisms, Herald Open Access | UCLA Health — Post-Infectious Cough
This is a shared conversation. Sign in to Orris to start your own chat.